COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Scientific title
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Secondary ID [1] 282441 0
Registration ID for Part 1 of this study: ACTRN12613000522718
Secondary ID [2] 282496 0
Registration ID for Part 2 of this study: ACTRN12613000527763
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 289050 0
Condition category
Condition code
Infection 289390 289390 0 0
Other infectious diseases

Study type
Description of intervention(s) / exposure
This is essentially a single centre, double-blind, randomised, placebo-controlled, ascending dose study in healthy subjects.

This study is divided into three parts.

The third part defines the pharmacokinetics, safety and tolerability following multiple oral dosing of DSM265. Three cohorts consisting of 8 subjects each, will be enrolled in this part.

This stage will begin after the completion of the last single-dose cohort. A suitable starting dose for Part 3 will be determined from the results of the analysis of drug levels in the blood of subjects from Part 1. Doses for Part 3 of the study will be selected to cover the predicted exposure that was effective in the pre-clinical studies.

Cohort B1: 6 subjects will receive x mg DSM265, 2 subjects placebo;
Cohort B2: 6 subjects will receive xx mg DSM265, 2 subjects placebo;
Cohort B3: 6 subjects will receive xxx mg DSM265, 2 subjects placebo.

Participants will be admitted to the study unit and will stay in the unit for the 5 days for drug administration and post dose follow up assessments. The mode of administration is an oral suspension of DSM265, administered as a single daily dose for 3 consecutive days. Participants in each cohort will receive the same dose on each day.
Intervention code [1] 287085 0
Treatment: Drugs
Comparator / control treatment
Placebo which will consist of an oral suspension of the vehicle used for preparation of DSM265, consisting of the same suspension, anti-foaming, and flavouring agents.
Control group

Primary outcome [1] 289511 0
The purpose of the study is to determine the maximum oral dose of DSM265 that can be tolerated by healthy adults.
Timepoint [1] 289511 0
Week 9

This will be determined by the PK results collected at the End of Study Visit at Week 9 of the overall trial.
Secondary outcome [1] 302660 0
Timepoint [1] 302660 0

Key inclusion criteria
1. Written informed consent must be obtained before any assessment is performed.
2. Healthy male and female (of non-childbearing potential) subjects age 18 to 55 years, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
a. Women are considered post-menopausal and not of child bearing potential if they have had at least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels at the local laboratory levels for post-menopause; or have had surgical bilateral oophorectomy or bilateral salpingectomy (with or without hysterectomy) at least six months ago. Women on oral contraceptives are to be excluded from the study, also women who have had a tubal ligation.
3. At screening and baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three (3) minutes and again when required after three (3) minutes in the standing position. Investigators can be guided by the following ranges:
a. oral body temperature between 35.0-37.5 degrees celsius
b. systolic blood pressure, 90-140 mm Hg
c. diastolic blood pressure, 50-90 mm Hg
d. pulse rate, 40-90 bpm
4. When blood pressure and pulse are taken after at least 3 minutes standing, there should be no more than a 20 mm Hg drop in systolic or 10 mm Hg drop in diastolic blood pressure and increase in heart rate (>20 bpm) (compared to the sitting results) associated with clinical manifestation of postural hypotension. Any subject exhibiting clinical manifestations of postural hypotension should be excluded.
5. Must have haematology, clinical chemistry and urinalysis results at screening that are within the reference range or, if outside the range, not clinically significant as judged by the investigator and confirmed and agreed by the medical monitor; aspartate aminotransferase (AST), ALT and bilirubin must be within the reference range at screening
6. Subjects must:
a. Weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18-30 kg/m2.
b. Be able to communicate well with the investigator, to understand and comply with the requirements of the study.
7. Good peripheral venous access
Minimum age
18 Years
Maximum age
55 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Known hypersensitivity to any of the study drugs.
2. Use of other investigational drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
3. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
4. A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at Screening or Baseline:
a. PR >210 msec
b. QRS complex >120 msec
c. QTcF >450 msec or shortened QTcF less than 340 msec or a family history of long QT syndrome or sudden death.
d. Second or third degree atrioventricular block.
e. Incomplete, full or intermittent bundle branch block.
f. Abnormal T wave morphology.
5. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
6. Pregnant or nursing (lactating) women.
7. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation
precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means.
8. Fertile males, defined as all males physiologically capable of conceiving offspring UNLESS the subject agrees to comply with two highly effective contraceptive methods comprising a barrier method (condom) for the entire duration of the study, and twelve weeks following the last study drug administration. Vasectomised males to use a condom for the entire study and 12 weeks following drug administration.
9. Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening and at each baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine greater than or equal to 500 ng/mL. For light smokers (defined as less than 5 cigarettes per day) to pass the cotinine test, smoking should be stopped at least 24 hours prior to reporting to the centre (i.e., Day -2, early morning). Smoking will not be allowed during the study.
10. Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing (note that diazepam interferes with the analysis of DSM265 and should not have been used for 8 weeks prior to initial dosing). If needed, (i.e. an incidental and limited need) paracetamol is acceptable up 4 g/day, but must be documented in the Concomitant medications / Significant non-drug therapies page of the CRF.
11. Intake of grapefruit, grapefruit juice or other products containing grapefruit within 14 days of the first drug administration.
12. Excessive intake of caffeine drinks or energy drinks within 48 hours before admission defined as more than three 8 oz. cups of coffee a day, equivalent to roughly 250 mg of caffeine. Defined as 1 (6oz) cup of coffee; 2 cans of cola; 1 (12oz) cup of tea; 3oz milk chocolate.
13. Consumption of broccoli, caviar, sardines, liver, heart and kidneys and yeast supplements one day prior to dosing and throughout the dosing phase. tomatoes and vegemite to be avoided 3 hours prior to dosing and 3 hours post dose.
14. Donation or loss of 400 mL or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
15. Plasma donation (>100 mL) within 60 days prior to first dosing.
16. Haemoglobin levels below 13.0 g/dL (males) or 11.5 g/dL (females) at screening as determined by Full Blood Cell (FBC) counts.
17. Haptoglobin levels outside reference range for study laboratory.
18. Positive direct antiglobulin test (direct Coomb’s test - DAT).
19. ALT and/or AST and/or lactase dehydrogenase (LDH) should be less than or equal to ULN.
20. Liver enzymes other than ALT, AST, LDH elevated greater than or equal to 1.5xULN within two (2) weeks prior to initial dosing.
21. Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).
22. Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
23. History of any food allergies.
24. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject’s medical history and/or clinical or laboratory evidence of any of the following:
i. Inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding in the last 6 months;
ii. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
iii. Pancreatic injury or pancreatitis in the last 6 months;
iv. The Investigator should be guided by the following criteria:
a. Any single parameter may not exceed 1.5 x upper limit of normal (ULN). A single parameter elevated up to and including 1.5 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to enrolment/randomisation, to rule out lab error.
b. Any elevation of more than one parameter excludes a subject from participation in the study unless otherwise agreed by the medical monitor. Testing may be repeated once more as soon as possible, but in all cases, at least prior to enrolment/randomisation, to rule out lab error.
Re-check results must not be clinically significant in order for subject to qualify and confirmed and agreed by the medical monitor.
25. History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or urea values, or abnormal urinary constituents (e.g., albuminuria).
26. Evidence of urinary obstruction or difficulty in voiding at screening.
27. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
28. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
29. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening and/or baseline.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
If a subject is deemed eligible for enrolment into the study and will commence dosing period, a randomisation/ treatment number will be assigned.

A sealed enveloped randomisation schedule will be provided to the site by the CRO for subjects to be randomised into a treatment sequence prior to the first dosing.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Subjects will be randomised as per the randomisation schedule provided by the CRO, and the randomisation number issued by the unblended pharmacist.

The method of sequence generation used was the simple randomisation within cohorts using a randomisation table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
This study is an ascending dose study being studied in 3 parts, and depending on the results of the previous parts, the study can then move on to the next part. It uses an adaptive design. If the pharmacokinetic parameters attain levels acceptable to the sponsor and Safety Review Team, the study will proceed to the induced malaria infection study. Likewise, if the pharmacodynamic parameters attain levels acceptable to the sponsor and Safety Review Team (SRT), the study will proceed to the multiple ascending dose (MAD) phase.
Phase 1
Type of endpoint(s)
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis

Recruitment status
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
Sponsor decision
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 287234 0
Name [1] 287234 0
Medicines for Malaria Venture
Address [1] 287234 0
Australian Centre for Vaccine Development,
300 Herston Road,
Country [1] 287234 0
Funding source category [2] 287236 0
Name [2] 287236 0
Queensland Institute of Medical Research
Address [2] 287236 0
300 Herston Road,
Country [2] 287236 0
Primary sponsor type
Commercial sector/Industry
CPR Pharma Services
28 Dalgleish Street,
Secondary sponsor category [1] 285986 0
Name [1] 285986 0
Address [1] 285986 0
Country [1] 285986 0

Ethics approval
Ethics application status
Ethics committee name [1] 289216 0
Quennsland Institute of Medical Research Human Ethics Committee
Ethics committee address [1] 289216 0
The Queensland Institute of Medical Research,
Post Office Royal Brisbane,
Ethics committee country [1] 289216 0
Date submitted for ethics approval [1] 289216 0
Approval date [1] 289216 0
Ethics approval number [1] 289216 0

Brief summary
The purpose of Part 3 of the study is to determine what the highest dose of DSM265 (study drug) is that can be safely given to people. This will be determined by how it makes people feel, how the body absorbs, processes and gets rid of DSM265 when receiving DSM265 every day for 3 days in increasing doses for the treatment of malaria.

This trial is to be conducted under the Australian Therapeutic Goods Administration (TGA) Clinical Trial Notification Scheme (CTN).
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 39778 0
Prof James McCarthy
Address 39778 0
Q-Pharm Pty Limited, Level 5,
300C Herston Road,
Country 39778 0
Phone 39778 0
+61 7 3845 3796
Fax 39778 0
+61 7 3362 0104
Email 39778 0
Contact person for public queries
Name 39779 0
Ms Gem Mackenroth
Address 39779 0
Q-Pharm Pty Ltd Level 5,
300 Herston Road/Level 6,
Block 8, Royal Brisbane and Women's Hospital,
Herston, QLD,
Country 39779 0
Phone 39779 0
+61 7 3845 3629
Fax 39779 0
+61 7 3845 3630
Email 39779 0
Contact person for scientific queries
Name 39780 0
Dr Suzanne Elliot
Address 39780 0
Q-Pharm Pty Ltd Level 5,
300 Herston Road/Level 6,
Block 8, Royal Brisbane and Women's Hospital,
Herston, QLD,
Country 39780 0
Phone 39780 0
+61 7 3845 3644
Fax 39780 0
+61 7 3845 3637
Email 39780 0

No information has been provided regarding IPD availability
Summary results
No Results